<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03310450</url>
  </required_header>
  <id_info>
    <org_study_id>0017</org_study_id>
    <nct_id>NCT03310450</nct_id>
  </id_info>
  <brief_title>Tour de Borobudur Troponin Study on Predictors and Synergistic Role of MDA and Hs-CRP Levels</brief_title>
  <acronym>TdBTS</acronym>
  <official_title>Predictors of Cardiac Troponin Release After Tour de Borobudur 2017</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitas Negeri Semarang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Research, Technology and Higher Education, Republic of Indonesia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universitas Diponegoro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitas Negeri Semarang</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective observational study to determine predictors that related to cardiac troponin I
      (cTnI) release, malondialdehyde (MDA) and high sensitivity C Reactive Protein (hs-CRP) after
      Tour de Borobudur (TdB) 2017
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Eligible Criteria:

        1. minimum sample size of 80 men, non-athlete, participants of TdB

        2. Classified into two groups: 160kms cycling and 100kms cycling participation

        3. 25-55 years old

        4. voluntary participate in the research

        5. eligible in pre participatory physical examination and ECG test by the doctor

        6. have no history of the previous acute coronary syndrome (ACS)

      Measurements:

      Interview for determining predictors of sports participation history, medical history, family
      medical history and Rate of Perceived Exertion Measurement and examination to determine:
      anthropometry parameters, clinical conditions (Systolic BP, Diastolic BP, hemoglobin levels,
      T-cholesterol and HDL-C levels, the intensity in cycling activities (mileage, velocity,
      duration, and time for resting), hemodynamic responses (average and maximum heart rate,
      Karvonen Index), and Hydration status

      Other outcome measurements; pre and post-TdB 2017 measurements of cTnI, MDA, and hs-CRP
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2017</start_date>
  <completion_date type="Actual">May 5, 2018</completion_date>
  <primary_completion_date type="Actual">November 11, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Cardiac Troponin I (cTnI)</measure>
    <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
    <description>specific protein to determine cardiac injury</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Malondialdehyde (MDA)</measure>
    <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
    <description>oxydative stress marker</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>High Sensitivity C Reactive Protein (Hs-CRP)</measure>
    <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
    <description>a biomarker that represents the inflammation process</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Pathological ECG Appearance</measure>
    <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
    <description>Number of Participants with Pathological ECG Appearance.
Pathological ECG appearance was the results of the ECG test describing one of the pathological appearances in ECG i.e.:
The pathological rhythm which is may consist of Atrial Flutter, Atrial Fibrillation, Supraventricular Tachycardia, Ventricular Fibrillation, First Degree Heart Block, Second Degree Heart Block, Type 1 - Mobitz I, Second Degree Heart Block, Type 2 - Mobitz II, Third Degree Heart Block, or other pathological rhythm appearances
Pathological ST-segment i.e. ST elevation (early repolarization), or another form
Pathological U wave, and
other pathological appearances</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">94</enrollment>
  <condition>Heart Arrest</condition>
  <condition>Sport Injury</condition>
  <condition>Inflammatory Response</condition>
  <condition>Oxidative Stress</condition>
  <arm_group>
    <arm_group_label>Group 140kms cycling</arm_group_label>
    <description>Participants of Tour de Borobudur 2017 140 km cycling touring and willing to participate in the study.
Investigator did not give any intervention, just observed the cycling touring event that the subjects participated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 100kms cycling</arm_group_label>
    <description>Participants of Tour de Borobudur 2017 100 km cycling touring and willing to participate in the study.
Investigator did not give any intervention, just observed the cycling touring event that the subjects participated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 240kms cycling</arm_group_label>
    <description>Participants of North Coast 2017 240 km cycling touring and willing to participate in the study.
Investigator did not give any intervention, just observed the cycling touring event that the subjects participated</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>140kms cycling</intervention_name>
    <description>Main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms, and 240kms (investigator did not give any treatment/intervention, just observed the cycling touring event)</description>
    <arm_group_label>Group 100kms cycling</arm_group_label>
    <arm_group_label>Group 140kms cycling</arm_group_label>
    <arm_group_label>Group 240kms cycling</arm_group_label>
    <other_name>medical history</other_name>
    <other_name>sports participation history</other_name>
    <other_name>clinical appearance</other_name>
    <other_name>lipid profile status</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        participants of Tour de Borobudur Indonesia 2017
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  minimum sample size of 80 men, non athlete, participants of TdB

          -  Classified into two groups: 160kms cycling and 100kms cycling participation

          -  25-55 years old

          -  voluntary participate in the research

          -  eligible in pre participatory physical examination and ECG test by doctor have no
             history of previous acute coronary syndrome (ACS)

        Exclusion Criteria:

          -  stop cycling before finish line due to mechanical or bicycle related errors

          -  (subjects who stop cycling due to any physical symptoms and health related problem
             included in analysis)
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mahalul Azam, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitas Negeri Semarang</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitas Negeri Semarang</name>
      <address>
        <city>Semarang</city>
        <state>Jawa Tengah</state>
        <zip>50229</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <reference>
    <citation>Serrano-Ostáriz E, Terreros-Blanco JL, Legaz-Arrese A, George K, Shave R, Bocos-Terraz P, Izquierdo-Álvarez S, Bancalero JL, Echavarri JM, Quilez J, Aragonés MT, Carranza-García LE. The impact of exercise duration and intensity on the release of cardiac biomarkers. Scand J Med Sci Sports. 2011 Apr;21(2):244-9. doi: 10.1111/j.1600-0838.2009.01042.x.</citation>
    <PMID>19919634</PMID>
  </reference>
  <reference>
    <citation>Grande G, Romppel M, Glaesmer H, Petrowski K, Herrmann-Lingen C. The type-D scale (DS14) - Norms and prevalence of type-D personality in a population-based representative sample in Germany. Pers Individ Dif [Internet]. 2010;48(8):935-9. Available from: http://dx.doi.org/10.1016/j.paid.2010.02.026</citation>
  </reference>
  <reference>
    <citation>Lee PH, Macfarlane DJ, Lam TH, Stewart SM. Validity of the International Physical Activity Questionnaire Short Form (IPAQ-SF): a systematic review. Int J Behav Nutr Phys Act. 2011 Oct 21;8:115. doi: 10.1186/1479-5868-8-115. Review.</citation>
    <PMID>22018588</PMID>
  </reference>
  <reference>
    <citation>Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research; Principles and quantitative methods. New York: John Wiley and Son Inc; 1982. 1-527 p.</citation>
  </reference>
  <reference>
    <citation>Bahrudin U, Morikawa K, Takeuchi A, Kurata Y, Miake J, Mizuta E, Adachi K, Higaki K, Yamamoto Y, Shirayoshi Y, Yoshida A, Kato M, Yamamoto K, Nanba E, Morisaki H, Morisaki T, Matsuoka S, Ninomiya H, Hisatome I. Impairment of ubiquitin-proteasome system by E334K cMyBPC modifies channel proteins, leading to electrophysiological dysfunction. J Mol Biol. 2011 Nov 4;413(4):857-78. doi: 10.1016/j.jmb.2011.09.006. Epub 2011 Sep 12.</citation>
    <PMID>21939669</PMID>
  </reference>
  <reference>
    <citation>Bahrudin U, Morisaki H, Morisaki T, Ninomiya H, Higaki K, Nanba E, Igawa O, Takashima S, Mizuta E, Miake J, Yamamoto Y, Shirayoshi Y, Kitakaze M, Carrier L, Hisatome I. Ubiquitin-proteasome system impairment caused by a missense cardiac myosin-binding protein C mutation and associated with cardiac dysfunction in hypertrophic cardiomyopathy. J Mol Biol. 2008 Dec 26;384(4):896-907. doi: 10.1016/j.jmb.2008.09.070. Epub 2008 Oct 7.</citation>
    <PMID>18929575</PMID>
  </reference>
  <reference>
    <citation>Purwowiyoto SL, Aryadi A, Suryaatmadja B, Ruray D, Purwowiyoto BS, Siswanto BB. Positive correlation between ECG dispersion mapping (heartvueTM) with T2DM patients. Glob Heart [Internet]. 2014;9(1):e243. Available from: http://linkinghub.elsevier.com/retrieve/pii/S221181601402119X</citation>
  </reference>
  <reference>
    <citation>de Koning L, Merchant AT, Pogue J, Anand SS. Waist circumference and waist-to-hip ratio as predictors of cardiovascular events: meta-regression analysis of prospective studies. Eur Heart J. 2007 Apr;28(7):850-6. Epub 2007 Apr 2. Review.</citation>
    <PMID>17403720</PMID>
  </reference>
  <reference>
    <citation>Shave R, George KP, Atkinson G, Hart E, Middleton N, Whyte G, Gaze D, Collinson PO. Exercise-induced cardiac troponin T release: a meta-analysis. Med Sci Sports Exerc. 2007 Dec;39(12):2099-106.</citation>
    <PMID>18046180</PMID>
  </reference>
  <reference>
    <citation>Morrow DA. Troponins in patients with acute coronary syndromes: biologic, diagnostic, and therapeutic implications. Cardiovasc Toxicol. 2001;1(2):105-10. Review.</citation>
    <PMID>12213981</PMID>
  </reference>
  <reference>
    <citation>Jassal DS, Moffat D, Krahn J, Ahmadie R, Fang T, Eschun G, Sharma S. Cardiac injury markers in non-elite marathon runners. Int J Sports Med. 2009 Feb;30(2):75-9. doi: 10.1055/s-0028-1104572. Epub 2009 Jan 28.</citation>
    <PMID>19177312</PMID>
  </reference>
  <reference>
    <citation>Rodondi N, Marques-Vidal P, Butler J, Sutton-Tyrrell K, Cornuz J, Satterfield S, Harris T, Bauer DC, Ferrucci L, Vittinghoff E, Newman AB; Health, Aging, and Body Composition Study. Markers of atherosclerosis and inflammation for prediction of coronary heart disease in older adults. Am J Epidemiol. 2010 Mar 1;171(5):540-9. doi: 10.1093/aje/kwp428. Epub 2010 Jan 28.</citation>
    <PMID>20110287</PMID>
  </reference>
  <reference>
    <citation>Eijsvogels TMH, Hoogerwerf MD, Maessen MFH, Seeger JPH, George KP, Hopman MTE, et al. Predictors of cardiac troponin release after a marathon. J Sci Med Sport [Internet]. 2015;18(1):88-92. Available from: http://dx.doi.org/10.1016/j.jsams.2013.12.002</citation>
  </reference>
  <reference>
    <citation>Serrano-Ostáriz E, Legaz-Arrese A, Terreros-Blanco JL, López-Ramón M, Cremades-Arroyos D, Carranza-García LE, Izquierdo-Alvarez S, Bocos-Terraz P. Cardiac biomarkers and exercise duration and intensity during a cycle-touring event. Clin J Sport Med. 2009 Jul;19(4):293-9. doi: 10.1097/JSM.0b013e3181ab3c9d. Erratum in: Clin J Sport Med. 2009 Sep;19(5):442. Carranza-García, Luis Enrique [added]; Alvarez-Izquierdo, Silvia [corrected to Izquierdo-Alvarez, Silvia]; Boscos-Terraz, Pilar [corrected to Bocos-Terraz, Pilar].</citation>
    <PMID>19638823</PMID>
  </reference>
  <reference>
    <citation>Eijsvogels T, George K, Shave R, Gaze D, Levine BD, Hopman MT, Thijssen DH. Effect of prolonged walking on cardiac troponin levels. Am J Cardiol. 2010 Jan 15;105(2):267-72. doi: 10.1016/j.amjcard.2009.08.679.</citation>
    <PMID>20102930</PMID>
  </reference>
  <reference>
    <citation>Neumayr G, Pfister R, Mitterbauer G, Maurer A, Gaenzer H, Sturm W, Hoertnagl H. Effect of the &quot;Race Across The Alps&quot; in elite cyclists on plasma cardiac troponins I and T. Am J Cardiol. 2002 Feb 15;89(4):484-6.</citation>
    <PMID>11835940</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 16, 2017</study_first_posted>
  <results_first_submitted>July 30, 2018</results_first_submitted>
  <results_first_submitted_qc>September 5, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">October 2, 2019</results_first_posted>
  <last_update_submitted>October 1, 2019</last_update_submitted>
  <last_update_submitted_qc>October 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>troponin-I</keyword>
  <keyword>hs-CRP</keyword>
  <keyword>Malondialdehyde</keyword>
  <keyword>predictors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Athletic Injuries</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03310450/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 12, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/50/NCT03310450/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Consecutive sampling was done by voluntary confirmation of participants in the 2017 North Coast tour (http://ina-northcoast-cyclingtour.com/index.html) and the 2017 Tour de Borobudur (https://event.sambabikers.com/). All participants were invited to participate in this observational study via an online advertisement on the website.</recruitment_details>
      <pre_assignment_details>Participants with a history of coronary artery diseases (CAD) were excluded from study participation. Subsequently, a total of 94 participants were included in this study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group 140kms Cycling</title>
          <description>willing to participate in 140kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="P2">
          <title>Group 100kms Cycling</title>
          <description>willing to participate in 100kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="P3">
          <title>Group 240kms Cycling</title>
          <description>willing to participate in 240kms cycling touring of NC 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="34"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>30 participants completed Tour de Borobudur 140K, 2017 30 participants completed Tour de Borobudur 100K, 2017 28 participantas completed North Coast Tour, 2017</population>
      <group_list>
        <group group_id="B1">
          <title>Group 140kms Cycling</title>
          <description>willing to participate in 140kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="B2">
          <title>Group 100kms Cycling</title>
          <description>willing to participate in 100kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="B3">
          <title>Group 240kms Cycling</title>
          <description>willing to participate in 240kms cycling touring of NC 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="88"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="43.3" spread="9.33"/>
                    <measurement group_id="B2" value="43.5" spread="10.18"/>
                    <measurement group_id="B3" value="49.0" spread="13.70"/>
                    <measurement group_id="B4" value="45.3" spread="11.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                    <count group_id="B4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Indonesia</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>cardiac troponin I (cTnI)</title>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="30"/>
                    <count group_id="B2" value="30"/>
                    <count group_id="B3" value="28"/>
                    <count group_id="B4" value="88"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.2" spread="9.98"/>
                    <measurement group_id="B2" value="6.6" spread="10.56"/>
                    <measurement group_id="B3" value="3.5" spread="8.93"/>
                    <measurement group_id="B4" value="5.2" spread="9.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cardiac Troponin I (cTnI)</title>
        <description>specific protein to determine cardiac injury</description>
        <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 140kms Cycling</title>
            <description>willing to participate in 140kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O2">
            <title>Group 100kms Cycling</title>
            <description>willing to participate in 100kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O3">
            <title>Group 240kms Cycling</title>
            <description>willing to participate in 240kms cycling touring of NC 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiac Troponin I (cTnI)</title>
          <description>specific protein to determine cardiac injury</description>
          <units>ng/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.6" spread="46.6"/>
                    <measurement group_id="O2" value="10.1" spread="10.44"/>
                    <measurement group_id="O3" value="25.0" spread="61.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Malondialdehyde (MDA)</title>
        <description>oxydative stress marker</description>
        <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 140kms Cycling</title>
            <description>willing to participate in 140kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O2">
            <title>Group 100kms Cycling</title>
            <description>willing to participate in 100kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O3">
            <title>Group 240kms Cycling</title>
            <description>willing to participate in 240kms cycling touring of NC 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
        </group_list>
        <measure>
          <title>Malondialdehyde (MDA)</title>
          <description>oxydative stress marker</description>
          <units>mcmol/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="206.1" spread="116.84"/>
                    <measurement group_id="O2" value="196.4" spread="68.59"/>
                    <measurement group_id="O3" value="231.2" spread="105.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>High Sensitivity C Reactive Protein (Hs-CRP)</title>
        <description>a biomarker that represents the inflammation process</description>
        <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group 140kms Cycling</title>
            <description>willing to participate in 140kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O2">
            <title>Group 100kms Cycling</title>
            <description>willing to participate in 100kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O3">
            <title>Group 240kms Cycling</title>
            <description>willing to participate in 240kms cycling touring of NC 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
        </group_list>
        <measure>
          <title>High Sensitivity C Reactive Protein (Hs-CRP)</title>
          <description>a biomarker that represents the inflammation process</description>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="454" spread="286.5"/>
                    <measurement group_id="O2" value="335" spread="375.1"/>
                    <measurement group_id="O3" value="350" spread="332.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Pathological ECG Appearance</title>
        <description>Number of Participants with Pathological ECG Appearance.
Pathological ECG appearance was the results of the ECG test describing one of the pathological appearances in ECG i.e.:
The pathological rhythm which is may consist of Atrial Flutter, Atrial Fibrillation, Supraventricular Tachycardia, Ventricular Fibrillation, First Degree Heart Block, Second Degree Heart Block, Type 1 - Mobitz I, Second Degree Heart Block, Type 2 - Mobitz II, Third Degree Heart Block, or other pathological rhythm appearances
Pathological ST-segment i.e. ST elevation (early repolarization), or another form
Pathological U wave, and
other pathological appearances</description>
        <time_frame>immediate after TdB 2017 cycling touring within less than 5 min</time_frame>
        <population>Pathological ECG appearance</population>
        <group_list>
          <group group_id="O1">
            <title>Group 140kms Cycling</title>
            <description>willing to participate in 140kms cycling touring of TdB 2017 140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O2">
            <title>Group 100kms Cycling</title>
            <description>willing to participate in 100kms cycling touring of TdB 2017 140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
          <group group_id="O3">
            <title>Group 240kms Cycling</title>
            <description>willing to participate in 240kms cycling touring of NC 2017 140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Pathological ECG Appearance</title>
          <description>Number of Participants with Pathological ECG Appearance.
Pathological ECG appearance was the results of the ECG test describing one of the pathological appearances in ECG i.e.:
The pathological rhythm which is may consist of Atrial Flutter, Atrial Fibrillation, Supraventricular Tachycardia, Ventricular Fibrillation, First Degree Heart Block, Second Degree Heart Block, Type 1 - Mobitz I, Second Degree Heart Block, Type 2 - Mobitz II, Third Degree Heart Block, or other pathological rhythm appearances
Pathological ST-segment i.e. ST elevation (early repolarization), or another form
Pathological U wave, and
other pathological appearances</description>
          <population>Pathological ECG appearance</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>during the event (cycling activity of TdB and NC) i.e. 6.1 hours range 3.5-9.8 and 24 hours after the event</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group 140kms Cycling</title>
          <description>willing to participate in 140kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="E2">
          <title>Group 100kms Cycling</title>
          <description>willing to participate in 100kms cycling touring of TdB 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
        <group group_id="E3">
          <title>Group 240kms Cycling</title>
          <description>willing to participate in 240kms cycling touring of NC 2017
140kms cycling: main exposure is long distance cycling touring (TdB/NC) consists of three groups; 140kms, 100kms and 240kms</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mahalul Azam</name_or_title>
      <organization>Universitas Negeri Semarang</organization>
      <phone>+628122853982</phone>
      <email>mahalul.azam@mail.unnes.ac.id</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

